
## **Oliver Rivero-Arias**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8250520/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epidemiology of fragile X syndrome: A systematic review and metaâ€analysis. American Journal of Medical Genetics, Part A, 2014, 164, 1648-1658.	0.7	320
2	Estimating the Association between SF-12 Responses and EQ-5D Utility Values by Response Mapping. Medical Decision Making, 2006, 26, 18-29.	1.2	188
3	Surgical stabilisation of the spine compared with a programme of intensive rehabilitation for the management of patients with chronic low back pain: cost utility analysis based on a randomised controlled trial. BMJ: British Medical Journal, 2005, 330, 1239.	2.4	136
4	Comparing the Efficacy of a Mobile Phone-Based Blood Glucose Management System With Standard Clinic Care in Women With Gestational Diabetes: Randomized Controlled Trial. JMIR MHealth and UHealth, 2018, 6, e71.	1.8	130
5	Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach. Value in Health, 2018, 21, 596-604.	0.1	129
6	Mapping the Modified Rankin Scale (mRS) Measurement into the Generic EuroQol (EQ-5D) Health Outcome. Medical Decision Making, 2010, 30, 341-354.	1.2	127
7	Valuation and Modeling of EQ-5D-5L Health States Using a Hybrid Approach. Medical Care, 2017, 55, e51-e58.	1.1	121
8	Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom. Cost Effectiveness and Resource Allocation, 2010, 8, 6.	0.6	100
9	Healthcare and social services resource use and costs of self-harm patients. Social Psychiatry and Psychiatric Epidemiology, 2011, 46, 263-271.	1.6	96
10	Effect of MRI on preterm infants and their families: a randomised trial with nested diagnostic and economic evaluation. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2018, 103, F15-F21.	1.4	86
11	Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?. Pharmacoeconomics, 2020, 38, 325-340.	1.7	86
12	Assessing the Use of a Feedback Module to Model EQ-5D-5L Health States Values in Hong Kong. Patient, 2018, 11, 235-247.	1.1	84
13	International Valuation Protocol for the EQ-5D-Y-3L. Pharmacoeconomics, 2020, 38, 653-663.	1.7	84
14	Evaluation of software for multiple imputation of semi-continuous data. Statistical Methods in Medical Research, 2007, 16, 243-258.	0.7	82
15	Prophylactic antibiotics in the prevention of infection after operative vaginal delivery (ANODE): a multicentre randomised controlled trial. Lancet, The, 2019, 393, 2395-2403.	6.3	81
16	Treatment Pathways, Resource Use, and Costs of Endovascular Coiling Versus Surgical Clipping After aSAH. Stroke, 2008, 39, 111-119.	1.0	74
17	The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration. Pharmacoeconomics, 2015, 33, 993-1011.	1.7	70
18	Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective. Value in Health, 2018, 21, 1291-1298.	0.1	70

OLIVER RIVERO-ARIAS

#	Article	IF	CITATIONS
19	Mapping EQ-5D Utility Scores from the PedsQLâ,,¢ Generic Core Scales. Pharmacoeconomics, 2014, 32, 693-706.	1.7	66
20	Normative Profile of Health-Related Quality of Life for Hong Kong General Population Using Preference-Based Instrument EQ-5D-5L. Value in Health, 2019, 22, 916-924.	0.1	61
21	Multiple imputation to deal with missing EQ-5D-3L data: Should we impute individual domains or the actual index?. Quality of Life Research, 2015, 24, 805-815.	1.5	60
22	Cost-Utility Analysis of Physiotherapy Treatment Compared With Physiotherapy Advice in Low Back Pain. Spine, 2006, 31, 1381-1387.	1.0	59
23	The effect of teamwork training on team performance and clinical outcome in elective orthopaedic surgery: a controlled interrupted time series study. BMJ Open, 2015, 5, e006216-e006216.	0.8	57
24	Cost-effectiveness of referral for generic care or problem-solving treatment from community mental health nurses, compared with usual general practitioner care for common mental disorders. British Journal of Psychiatry, 2006, 189, 50-59.	1.7	54
25	The current practice of handling and reporting missing outcome data in eight widely used PROMs in RCT publications: a review of the current literature. Quality of Life Research, 2016, 25, 1613-1623.	1.5	53
26	Responsiveness of Objective, Disease-Specific, and Generic Outcome Measures in Patients With Chronic Low Back Pain: An Assessment for Improving, Stable, and Deteriorating Patients. Spine, 2006, 31, 815-822.	1.0	45
27	Eq5d: A command to Calculate Index Values for the EQ-5D Quality-of-life Instrument. The Stata Journal, 2011, 11, 120-125.	0.9	44
28	A combined teamwork training and work standardisation intervention in operating theatres: controlled interrupted time series study. BMJ Quality and Safety, 2015, 24, 111-119.	1.8	43
29	Multiple imputation for patient reported outcome measures in randomised controlled trials: advantages and disadvantages of imputing at the item, subscale or composite score level. BMC Medical Research Methodology, 2018, 18, 87.	1.4	42
30	Effect of Self-monitoring of Blood Pressure on Diagnosis of Hypertension During Higher-Risk Pregnancy. JAMA - Journal of the American Medical Association, 2022, 327, 1656.	3.8	40
31	A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATECIC). Health Technology Assessment, 2016, 20, 1-138.	1.3	36
32	Effect of Self-monitoring of Blood Pressure on Blood Pressure Control in Pregnant Individuals With Chronic or Gestational Hypertension. JAMA - Journal of the American Medical Association, 2022, 327, 1666.	3.8	34
33	Gestational age and hospital admissions during childhood: population based, record linkage study in England (TIGAR study). BMJ, The, 2020, 371, m4075.	3.0	33
34	Blood pressure monitoring in high-risk pregnancy to improve the detection and monitoring of hypertension (the BUMP 1 and 2 trials): protocol for two linked randomised controlled trials. BMJ Open, 2020, 10, e034593.	0.8	30
35	Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?. Medical Decision Making, 2021, 41, 584-596.	1.2	30
36	Healthcare and wider societal implications of stillbirth: a populationâ€based costâ€ofâ€illness study. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 108-117.	1.1	29

OLIVER RIVERO-ARIAS

#	Article	IF	CITATIONS
37	Dealing with the health state â€ <sup>~</sup> dead' when using discrete choice experiments to obtain values for EQ-5D-5L heath states. European Journal of Health Economics, 2013, 14, 33-42.	1.4	28
38	Beyond maternal death: improving the quality of maternal care through national studies of †near-miss' maternal morbidity. Programme Grants for Applied Research, 2016, 4, 1-180.	0.4	26
39	Accounting for Unobservable Preference Heterogeneity and Evaluating Alternative Anchoring Approaches to Estimate Country-Specific EQ-5D-Y Value Sets: A Case Study Using Spanish Preference Data. Value in Health, 2022, 25, 835-843.	0.1	26
40	Effectiveness of facilitated introduction of a standard operating procedure into routine processes in the operating theatre: a controlled interrupted time series. BMJ Quality and Safety, 2015, 24, 120-127.	1.8	25
41	Valuing child and adolescent health: a qualitative study on different perspectives and priorities taken by the adult general public. Health and Quality of Life Outcomes, 2021, 19, 222.	1.0	24
42	Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. Pharmacoeconomics, 2015, 33, 985-991.	1.7	21
43	The costs and prognostic characteristics of ischaemic neurological deficit due to subarachnoid haemorrhage in the United Kingdom. Journal of Neurology, 2009, 256, 364-373.	1.8	20
44	Feasibility, Validity and Differences in Adolescent and Adult EQ-5D-Y Health State Valuation in Australia and Spain: An Application of Best–Worst Scaling. Pharmacoeconomics, 2020, 38, 499-513.	1.7	19
45	Survival, Dependency, and Health-Related Quality of Life in Patients With Ruptured Intracranial Aneurysm: 10-Year Follow-up of the United Kingdom Cohort of the International Subarachnoid Aneurysm Trial. Neurosurgery, 2021, 88, 252-260.	0.6	18
46	Hypothermia for perinatal asphyxia: trial-based quality of life at 6–7 years. Archives of Disease in Childhood, 2018, 103, 654-659.	1.0	17
47	A multicentre, randomised controlled trial of position during the late stages of labour in nulliparous women with an epidural: clinical effectiveness and an economic evaluation (BUMPES). Health Technology Assessment, 2017, 21, 1-176.	1.3	15
48	Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement. Quality of Life Research, 2016, 25, 275-281.	1.5	14
49	Patient preferences for management of high blood pressure in the UK: a discrete choice experiment. British Journal of General Practice, 2019, 69, e629-e637.	0.7	14
50	The Multinational Nature of Cost-Effectiveness Analyses Alongside Multinational Clinical Trials. Value in Health, 2010, 13, 34-41.	0.1	13
51	Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement. Health and Quality of Life Outcomes, 2015, 13, 106.	1.0	13
52	Hypothermia for perinatal asphyxia: trial-based resource use and costs at 6–7 years. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2019, 104, F285-F292.	1.4	13
53	Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study. PLoS ONE, 2016, 11, e0150032.	1.1	13
54	Computerised interpretation of the fetal heart rate during labour: a randomised controlled trial (INFANT). Health Technology Assessment, 2018, 22, 1-186.	1.3	13

OLIVER RIVERO-ARIAS

#	Article	IF	CITATIONS
55	What do we know about managing Dupuytren's disease cost-effectively?. BMC Musculoskeletal Disorders, 2018, 19, 34.	0.8	11
56	Exploring women's preferences for birth settings in England: A discrete choice experiment. PLoS ONE, 2019, 14, e0215098.	1.1	11
57	Gestational age at birth and child special educational needs: a UK representative birth cohort study. Archives of Disease in Childhood, 2021, 106, 842-848.	1.0	11
58	Lean Participative Process Improvement: Outcomes and Obstacles in Trauma Orthopaedics. PLoS ONE, 2016, 11, e0152360.	1.1	10
59	Comparison of statistical approaches for analyzing incomplete longitudinal patient-reported outcome data in randomized controlled trials. Patient Related Outcome Measures, 2018, Volume 9, 197-209.	0.7	10
60	Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment–Based Valuation Studies Affect Health Preferences?. Value in Health, 2022, 25, 1196-1204.	0.1	10
61	Scoring system to facilitate diagnosis of Gaucher disease. Internal Medicine Journal, 2020, 50, 1538-1546.	0.5	9
62	The Impact of Risk Management Standards on Patient Safety: The Determinants of MRSA Infections in Acute NHS Hospitals, 2001–08*. Oxford Bulletin of Economics and Statistics, 2013, 75, 340-361.	0.9	8
63	Response Mapping to Translate Health Outcomes into the Generic Health-Related Quality-of-Life Instrument EQ-5D: Introducing the mrs2eq and oks2eq Commands. The Stata Journal, 2013, 13, 474-491.	0.9	8
64	Autoimmune markers for the diagnosis of rheumatoid arthritis in primary care: primary care diagnostic technology update. British Journal of General Practice, 2013, 63, 553-554.	0.7	7
65	PREFERRED REPORTING ITEMS FOR STUDIES MAPPING ONTO PREFERENCE-BASED OUTCOME MEASURES: THE MAPS STATEMENT. International Journal of Technology Assessment in Health Care, 2015, 31, 230-235.	0.2	7
66	The societal monetary value of a QALY associated with EQ-5D-3L health gains. European Journal of Health Economics, 2020, 21, 363-379.	1.4	7
67	Optimising neonatal service provision for preterm babies born between 27 and 31 weeks gestation in England (OPTI-PREM), using national data, qualitative research and economic analysis: a study protocol. BMJ Open, 2019, 9, e029421.	0.8	6
68	Preferences for interventions designed to increase cervical screening uptake in nonâ€attending young women: How findings from a discrete choice experiment compare with observed behaviours in a trial. Health Expectations, 2020, 23, 202-211.	1.1	5
69	Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement. Journal of Medical Economics, 2015, 18, 851-857.	1.0	4
70	Intravenous co-amoxiclav to prevent infection after operative vaginal delivery: the ANODE RCT. Health Technology Assessment, 2019, 23, 1-54.	1.3	4
71	Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. Diabetes Care, 2020, 43, 2485-2492.	4.3	3
72	Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren's disease: Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD). Wellcome Open Research, 2018, 3, 156.	0.9	3

#	Article	IF	CITATIONS
73	Safer delivery of surgical services: a programme of controlled before-and-after intervention studies with pre-planned pooled data analysis. Programme Grants for Applied Research, 2016, 4, 1-170.	0.4	3
74	Exploring the use of health and wellbeing measures during pregnancy and the first year following birth in women living with pre-existing long-term conditions: qualitative interviews with women and healthcare professionals. BMC Health Services Research, 2021, 21, 597.	0.9	2
75	Methods for evaluating the benefits and harms of antenatal and newborn screening programmes adopted by health economic assessments: protocol for a systematic review. BMJ Open, 2021, 11, e048031.	0.8	2
76	Using stated-preferences methods to develop a summary metric to determine successful treatment of children with a surgical condition: a study protocol. BMJ Open, 2022, 12, e062833.	0.8	2
77	Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. Medical Decision Making, 2015, 35, NP1-NP8.	1.2	1
78	Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. Applied Health Economics and Health Policy, 2015, 13, 437-443.	1.0	1
79	The way forward to a renewed and improved Health and Quality of Life Outcomes. Health and Quality of Life Outcomes, 2021, 19, 109.	1.0	1
80	Is a simple "Thank you" too much to ask?. BMJ: British Medical Journal, 2009, 339, b3683-b3683.	2.4	1
81	Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren's disease: Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD). Wellcome Open Research, 2018, 3, 156.	0.9	1
82	Prophylactic Antibiotics in the Prevention of Infection After Operative Vaginal Delivery (ANODE): A Multicenter Randomized Controlled Trial. Obstetrical and Gynecological Survey, 2019, 74, 635-637.	0.2	0
83	Economic evaluation of computerised interpretation of fetal heart rate during labour: a cost-consequence analysis alongside the INFANT study. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2021, 106, 143-148.	1.4	0
84	Late pregnancy ultrasound parameters identifying fetuses at risk of adverse perinatal outcomes: a protocol for a systematic review of systematic reviews. BMJ Open, 2022, 12, e058293.	0.8	0